Clinical trial
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
NCT00320229 is registered in ClinicalTrials.gov with Azienda Sanitaria Ospedaliera as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
- Lead sponsor
- Azienda Sanitaria Ospedaliera
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- December 31, 2004
- Completion date
- July 31, 2005
- Enrollment
- 84
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.